PT-141 (Bremelanotide)

PT-141 (Bremelanotide) at a Glance

PT-141 (bremelanotide) is a melanocortin-receptor agonist that acts in the brain rather than on blood vessels, which makes it mechanistically unlike the PDE5 inhibitors used for erectile dysfunction — it targets desire rather than the vascular response. It is FDA-approved as Vyleesi, an on-demand subcutaneous injection for hypoactive sexual desire disorder in premenopausal women. It originated as a byproduct of research into melanotan-II, when the sexual effects seen in early tanning studies turned out to be the more developable property.

History & Development

PT-141 exists because of an unexpected observation in a tanning study: the compound being tested for pigmentation kept producing sexual arousal, and that side effect became a drug.

First described	Derived from melanotan-II, itself descended from the 1980 alpha-MSH analogue work 24Reference 24Sawyer et al. · 1980Sawyer, T. K., Sanfilippo, P. J., Hruby, V. J., Engel, M. H., Heward, C. B., Burnett, J. B., & Hadley, M. E. (1980). 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proceedings of the National Academy of Sciences, 77(10), 5754-5758. https://pubmed.ncbi.nlm.nih.gov/6777774/View study →
Discovered / synthesised by	Developed by Palatin Technologies from the University of Arizona melanocortin programme 24,25Reference 24Sawyer et al. · 1980Sawyer, T. K., Sanfilippo, P. J., Hruby, V. J., Engel, M. H., Heward, C. B., Burnett, J. B., & Hadley, M. E. (1980). 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proceedings of the National Academy of Sciences, 77(10), 5754-5758. https://pubmed.ncbi.nlm.nih.gov/6777774/View study →Reference 25Arizona Daily StarUA-developed synthetic hormones speed a tanView study →
Institution	Palatin Technologies; originating chemistry from the University of Arizona 24,25Reference 24Sawyer et al. · 1980Sawyer, T. K., Sanfilippo, P. J., Hruby, V. J., Engel, M. H., Heward, C. B., Burnett, J. B., & Hadley, M. E. (1980). 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proceedings of the National Academy of Sciences, 77(10), 5754-5758. https://pubmed.ncbi.nlm.nih.gov/6777774/View study →Reference 25Arizona Daily StarUA-developed synthetic hormones speed a tanView study →
Origin	Synthetic melanocortin-receptor agonist; active metabolite of melanotan-II
Key patent	US 7,307,063, “Melanocortin metallopeptides for treatment of sexual dysfunction” 26Reference 26US Patent 7 et al.Melanocortin metallopeptides for treatment of sexual dysfunctionView study →
Assignee	Palatin Technologies
Development status	Approved - FDA, 21 June 2019, as Vyleesi for acquired generalized HSDD in premenopausal women

Discovery

The lineage starts with the University of Arizona melanocortin programme, whose 1980 PNAS paper described the superpotent alpha-MSH analogue that all of these compounds descend from ^{24Reference 24Sawyer et al. · 1980Sawyer, T. K., Sanfilippo, P. J., Hruby, V. J., Engel, M. H., Heward, C. B., Burnett, J. B., & Hadley, M. E. (1980). 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proceedings of the National Academy of Sciences, 77(10), 5754-5758. https://pubmed.ncbi.nlm.nih.gov/6777774/View study →}. Its cyclic successor, melanotan-II, was being tested as a sunless-tanning and chemoprevention agent when male subjects reported spontaneous erections and increased sexual arousal ^{25Reference 25Arizona Daily StarUA-developed synthetic hormones speed a tanView study →}.

That finding was the drug. Bremelanotide is essentially the active metabolite of melanotan-II, and developing it meant pursuing the effect that the tanning programme had treated as an adverse event.

What makes it pharmacologically distinctive followed from this origin: it acts on melanocortin receptors in the central nervous system rather than on blood vessels, so it addresses desire rather than the vascular response that PDE5 inhibitors target. That is why it was developed for women, and for a desire disorder, rather than as another erectile-dysfunction drug.

Development & ownership

Palatin Technologies took the compound forward, with patent protection including US 7,307,063, “Melanocortin metallopeptides for treatment of sexual dysfunction” ^{26Reference 26US Patent 7 et al.Melanocortin metallopeptides for treatment of sexual dysfunctionView study →}. Development partnered with AMAG Pharmaceuticals for commercialisation.

An earlier intranasal formulation was discontinued after blood-pressure increases were observed, and the programme was reworked as a subcutaneous on-demand injection - the form that succeeded. The FDA approved it as Vyleesi on 21 June 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women.

How it reached the market

PT-141 is available both ways, which is unusual. The approved product is a prescription autoinjector used on demand ahead of anticipated activity. Separately, “PT-141” is sold widely as an unapproved research chemical in lyophilised form for self-injection by both sexes - outside the approved indication, the approved population and any dose oversight.

What It's Used For

PT-141 (bremelanotide) is a synthetic cyclic seven-amino-acid melanocortin-receptor agonist — Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH — and the free-acid metabolite of the tanning peptide melanotan II. Unlike PDE5 inhibitors, which act on penile vasculature, it works centrally on melanocortin (chiefly MC4R) pathways that gate sexual desire and arousal ^{16,23Reference 16Molinoff PB et al. · 2003ReviewPT-141: a melanocortin agonist for the treatment of sexual dysfunction — early clinical reviewView study →Reference 23Pfaus JG et al. · 2022ReviewThe neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women — review (mechanism)View study →}.

Its evidence posture is unusual for a compound sold as a “research peptide”: one indication — acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women — is backed by two large phase 3 RCTs and carries a June 2019 FDA approval under the brand name Vyleesi ^{1,7Reference 1Kingsberg SA et al. · 2019RCTBremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials — human (RCT)View study →Reference 7Dhillon S · 2019ReviewBremelanotide: First Approval — regulatory reviewView study →}.

That approval is real, and it is also narrow. Every other use — male erectile dysfunction, general “libido enhancement,” fat loss — rests on older, smaller, or discontinued human work, or on preclinical data, even though the gray-market peptide is sold broadly for all of them. Route is load-bearing: it is a subcutaneous injection because the cyclic peptide’s oral bioavailability is negligible ^{18Reference 18Sauter M et al. · 2020Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics — analytical / PKView study →}.

Evidence by IndicationStrength of support · Beta

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric. Each application links down to its write-up.

01Female hypoactive sexual desire disorder (HSDD)Proven80%FDA-approved; two phase 3 human RCTs + 52-week extension + phase 2b dose-finding. Modest, contested effect sizes ^{1,2,3,9,10Reference 1Kingsberg SA et al. · 2019RCTBremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials — human (RCT)View study →Reference 2Simon JA et al. · 2019Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder — human (52-week open-label extension)View study →Reference 3Clayton AH et al. · 2016RCTBremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial — human (RCT, phase 2b)View study →Reference 9Spielmans GI · 2021Re-Analyzing Phase III Bremelanotide Trials for “Hypoactive Sexual Desire Disorder” in Women — re-analysis / critiqueView study →Reference 10Spielmans GI · 2024Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder — critical analysisView study →}.

02Male erectile dysfunctionPromising52%Small older human RCTs (intranasal/SC); program discontinued; the pivotal salvage trial is under an Expression of Concern ^{11,12,13,14,15Reference 11Safarinejad MR · 2008RCTSalvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study — human (RCT; see reference 12)View study →Reference 12Safarinejad MR · 2023RCTExpression of Concern: Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study — editorial noticeView study →Reference 13Rosen RC et al. · 2004Clinical trialEvaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141 — human (clinical trial)View study →Reference 14Diamond LE et al. · 2004RCTDouble-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141 — human (clinical trial)View study →Reference 15Diamond LE et al. · 2005Clinical trialCo-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction — human (clinical trial)View study →}.

03Weight loss / obesityShaky42%Two short phase 1 human RCTs (~1.3 kg over 16 days); one ongoing phase 2 combination study. Tiny and brief ^{17Reference 17Spana C et al. · 2022RCTEffect of bremelanotide on body weight of obese women: data from two phase 1 randomized controlled trials — human (RCT, phase 1)View study →}.

04Anti-cancer (glioblastoma)Shaky12%A single in-vitro study in cell lines; no animal or human data ^{20Reference 20Suzuki S et al. · 2024In vitroMelanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression — in vitroView study →}.

Mechanisms

Pharmacokinetics

Bremelanotide is given subcutaneously; the marketed Vyleesi product is a 1.75 mg / 0.3 mL single-use prefilled autoinjector delivered to the abdomen or thigh. The cyclic heptapeptide has negligible oral bioavailability, which is precisely why oral and intranasal routes were not carried into the approved product ^{18Reference 18Sauter M et al. · 2020Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics — analytical / PKView study →}. After subcutaneous dosing, peak plasma concentration is reached at roughly 1 hour and the elimination half-life is short — about 2.7 hours after a single dose. It is cleared by peptide hydrolysis with renal and faecal elimination, and the label advises against use in significant renal impairment. Experimental delivery work reinforces the route constraint rather than relieving it: an ultra-sensitive UHPLC-MS/MS study was needed simply to quantify oral plasma exposure ^{18Reference 18Sauter M et al. · 2020Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics — analytical / PKView study →}, and a biodegradable transbuccal “suction patch” reported roughly 26% relative bioavailability in dogs ^{19Reference 19Krupke H et al. · 2025A biodegradable suction patch for sustainable transbuccal peptide delivery — animal (dog, delivery study)View study →} — preclinical delivery engineering, not an available non-injected human product. For gray-market lyophilized powder, reconstitution (typically with bacteriostatic water) and cold storage are required, and neither potency nor sterility is verifiable by the end user.

Clinical & regulatory status

Bremelanotide is an FDA-approved prescription drug — Vyleesi, approved 21 June 2019, developed by Palatin Technologies with AMAG Pharmaceuticals — for acquired, generalized HSDD in premenopausal women ^{7,8Reference 7Dhillon S · 2019ReviewBremelanotide: First Approval — regulatory reviewView study →Reference 82019ReviewBremelanotide (Vyleesi) for hypoactive sexual desire disorder — reviewView study →}. It is a genuine, regulator-reviewed medicine for that indication and not a dietary supplement. It is not approved by the EMA: the European marketing application was withdrawn. It has no approved indication in men, and none for erectile dysfunction, tanning, or weight loss. Registered-trial activity is concentrated in HSDD (the completed phase 3 program plus supporting phase 1–4 studies), with one ongoing phase 2 obesity combination study (NCT06565611). There are no registered human trials of the general community “libido peptide” dosing pattern. The counts below reflect what is findable and verifiable in PubMed and ClinicalTrials.gov in this pass.

Last checked: July 2026.

Sourcing, Route & Legal Status

Regulatory status. Bremelanotide is an FDA-approved prescription drug, marketed as Vyleesi, approved 21 June 2019 for acquired, generalized HSDD in premenopausal women ^{7Reference 7Dhillon S · 2019ReviewBremelanotide: First Approval — regulatory reviewView study →}. That approval covers one indication in one population — it is not a general endorsement of the molecule, and it does not transfer to any other use. It is not approved by the EMA (the European application was withdrawn), and it has no approved indication in men, for erectile dysfunction, for tanning, or for weight loss. Anything sold as “PT-141” for those purposes is either off-label prescribing or an unapproved research chemical in that context. It is not a scheduled or controlled substance in the US, but “not scheduled” is not “approved,” and marketing it for human use outside the approved indication is unlawful in most Western jurisdictions.

How it’s supplied & administered. The approved product is a single-use prefilled autoinjector delivering 1.75 mg in 0.3 mL subcutaneously (abdomen or thigh), taken on demand at least 45 minutes before anticipated sexual activity, with a labeled ceiling of one dose per 24 hours and eight per month. The subcutaneous route is not a stylistic choice: the cyclic peptide’s oral bioavailability is negligible ^{18Reference 18Sauter M et al. · 2020Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics — analytical / PKView study →}, so an oral “PT-141” cannot deliver meaningful systemic exposure regardless of what the label claims. Gray-market material is instead sold as lyophilized powder requiring user reconstitution — typically with bacteriostatic water — followed by refrigerated storage; reconstituted peptide is chemically less stable and has a short shelf life.

Sourcing reality (this is a safety issue, not a footnote). Outside the regulated autoinjector, PT-141 is sold widely by unregulated peptide vendors labeled “for research use only / not for human consumption.” These products carry the standard research-peptide risks: no manufacturing oversight, unverified purity and peptide content, possible mislabeling or under-/over-concentration, bacterial endotoxin, and sterility or dosing errors introduced by the end user during reconstitution. A vendor certificate of analysis is only as good as the third-party lab behind it, and can be falsified. The decisive point is that gray-market powder is not the same regulated entity as Vyleesi even when the molecule is nominally identical — the approval attaches to a manufactured, tested product, not to a sequence. No vendors are recommended or linked here.

Safety

Bremelanotide has two dose-limiting effects that are different in kind — nausea is why people stop, and the transient blood-pressure rise is why the label restricts who may take it at all. It is a prescription drug, and gray-market powder carries risks the approved autoinjector does not.

Safety at a Glance

⚠️ Moderate toxicityCardiac cautionCardiac riskDrug interactions

• Contraindicated in uncontrolled hypertension or known cardiovascular disease. Each dose transiently raises blood pressure and lowers heart rate.
• Avoid in pregnancy. The label advises discontinuing if pregnancy is suspected — see the box below.
• Not for use in significant renal or hepatic impairment.
• Nausea is the tolerability limit. The most common complaint in the pivotal trials, and enough to make some participants discontinue.
• Slows gastric emptying. Can reduce absorption of oral drugs taken with it, notably oral naltrexone.
• Focal hyperpigmentation with repeated dosing. Darkening of the face, gums or breasts via MC1R-driven melanogenesis.

Full Safety & Interactions Detail

Adverse effects. In the pivotal trials the most common treatment-emergent effects were nausea, flushing, headache, and injection-site reactions, each occurring in at least 10% of participants; nausea was the most common complaint and led some participants to discontinue ^{1,5Reference 1Kingsberg SA et al. · 2019RCTBremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials — human (RCT)View study →Reference 5Clayton AH et al. · 2022Safety Profile of Bremelanotide Across the Clinical Development Program — human (pooled safety analysis)View study →}. Bremelanotide transiently raises blood pressure and lowers heart rate after each dose — on ambulatory blood-pressure monitoring, systolic pressure rose roughly 2–4 mmHg over placebo, peaking within hours and generally resolving within a day ^{6Reference 6White WB et al. · 2017RCTUsefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide — human (randomised pharmacodynamic study)View study →}. With repeated dosing it can cause focal hyperpigmentation — darkening of the face, gums, or breasts — through MC1R-driven melanogenesis ^{5Reference 5Clayton AH et al. · 2022Safety Profile of Bremelanotide Across the Clinical Development Program — human (pooled safety analysis)View study →}.

Dose-limiting effects. Two, and they are different in kind: nausea (tolerability, the reason people stop) and the blood-pressure rise (cardiovascular, the reason the label restricts who may take it).

Interactions. The blood-pressure effect is the basis of the main caution — it should not be combined with anything for which a transient pressor response is dangerous. Bremelanotide also slows gastric emptying, so it can reduce the rate and extent of absorption of concomitantly taken oral drugs; the label specifically warns that it may significantly decrease exposure to oral naltrexone, potentially causing naltrexone to fail. A dedicated ethanol-interaction study was conducted in the development program. Broader drug-interaction screening for off-label or community use has not been done.

Who should avoid it. It is contraindicated in uncontrolled hypertension or known cardiovascular disease, and is not for use in significant renal or hepatic impairment. The label advises stopping if there is no benefit after about eight weeks. It has not been studied or approved in postmenopausal women or in men, and anyone unwilling to accept an unregulated product of unverified purity should not use gray-market material.

Injection-specific risks. Injection-site reactions are common even with the regulated autoinjector. Gray-market lyophilized powder adds sterility failure, contamination, endotoxin exposure, and dosing error from self-mixed concentrations — risks that do not apply to the approved product.

Scope disclosure (honesty, not a claim):

• Human data? Yes for the approved indication — two phase 3 RCTs plus a 52-week open-label extension in premenopausal HSDD. Thin and older for male ED; phase 1 only for weight loss; none for general community “libido” dosing.
• Interactions assessed? Partly — oral-drug absorption (naltrexone) and alcohol were assessed in the approval program. Broad interaction screening for off-label use was not done.
• Pregnancy/lactation assessed? Partly — the label advises against use in pregnancy, and a lactation pharmacokinetic study was run, but safety in both is not established.
• Long-term safety established? No beyond the ~52-week open-label extension in HSDD ^{2Reference 2Simon JA et al. · 2019Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder — human (52-week open-label extension)View study →}. There is no long-term safety data for off-label or chronic use.

Never imply safety from silence. Where bremelanotide has not been studied — off-label libido dosing, chronic use, male metabolic use, gray-market product purity — the correct statement is “not assessed,” not “safe.”

Pregnancy & Lactation

⚠ Avoid in pregnancy? Not established in lactation

Avoid in pregnancy; not established in lactation. The label advises discontinuing if pregnancy is suspected, and there is no established safety in pregnancy. A phase 4 lactation study (NCT06867835) measured drug concentrations in lactating women, but breastfeeding safety is not established on that basis.

Dosage

The only established dose is the approved prescribing regimen for one indication, and it is reproduced here as data, not as a recommendation. For acquired, generalized HSDD in premenopausal women, Vyleesi is 1.75 mg subcutaneously as needed, injected into the abdomen or thigh at least 45 minutes before anticipated sexual activity, with a labeled maximum of one dose per 24 hours and eight doses per month; the label advises discontinuing if there is no benefit after roughly eight weeks. That regimen came out of the phase 2b dose-finding work and was carried into the phase 3 trials ^{1,3,4Reference 1Kingsberg SA et al. · 2019RCTBremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials — human (RCT)View study →Reference 3Clayton AH et al. · 2016RCTBremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial — human (RCT, phase 2b)View study →Reference 4Althof S et al. · 2019RCTResponder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide — human (RCT, secondary analysis)View study →}.

There is no established dose for any other use. Male erectile dysfunction, general arousal enhancement, and fat loss have no approved or validated dosing — the male-ED trials used a discontinued intranasal formulation and different amounts ^{14,15Reference 14Diamond LE et al. · 2004RCTDouble-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141 — human (clinical trial)View study →Reference 15Diamond LE et al. · 2005Clinical trialCo-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction — human (clinical trial)View study →}, and the weight-loss data come from 16-day phase 1 protocols ^{17Reference 17Spana C et al. · 2022RCTEffect of bremelanotide on body weight of obese women: data from two phase 1 randomized controlled trials — human (RCT, phase 1)View study →}. Community dosing figures for gray-market powder derive from vendor copy and forum practice, not from controlled human dose-finding, and reconstituting lyophilized powder introduces a concentration error the approved autoinjector does not have. Because the compound raises blood pressure at therapeutic doses ^{6Reference 6White WB et al. · 2017RCTUsefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide — human (randomised pharmacodynamic study)View study →}, dose-stacking is not a benign experiment. This entry is informational only and is not medical advice.

References

1. Kingsberg SA, et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials — human (RCT). Obstetrics & Gynecology. https://pubmed.ncbi.nlm.nih.gov/31599840/
2. Simon JA, et al. (2019). Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder — human (52-week open-label extension). Obstetrics & Gynecology. https://pubmed.ncbi.nlm.nih.gov/31599847/
3. Clayton AH, et al. (2016). Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial — human (RCT, phase 2b). Women’s Health (London). https://pubmed.ncbi.nlm.nih.gov/27181790/
4. Althof S, et al. (2019). Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide — human (RCT, secondary analysis). Journal of Sexual Medicine. https://pubmed.ncbi.nlm.nih.gov/31277966/
5. Clayton AH, et al. (2022). Safety Profile of Bremelanotide Across the Clinical Development Program — human (pooled safety analysis). Journal of Women’s Health. https://pubmed.ncbi.nlm.nih.gov/35147466/
6. White WB, et al. (2017). Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide — human (randomised pharmacodynamic study). Journal of Hypertension. https://pubmed.ncbi.nlm.nih.gov/27977473/
7. Dhillon S, Keam SJ. (2019). Bremelanotide: First Approval — regulatory review. Drugs. https://pubmed.ncbi.nlm.nih.gov/31429064/
8. (2019). Bremelanotide (Vyleesi) for hypoactive sexual desire disorder — review. The Medical Letter on Drugs and Therapeutics. https://pubmed.ncbi.nlm.nih.gov/31381550/
9. Spielmans GI. (2021). Re-Analyzing Phase III Bremelanotide Trials for “Hypoactive Sexual Desire Disorder” in Women — re-analysis / critique. Journal of Sex Research. https://pubmed.ncbi.nlm.nih.gov/33678061/
10. Spielmans GI. (2024). Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder — critical analysis. Journal of Sex Research. https://pubmed.ncbi.nlm.nih.gov/36809187/
11. Safarinejad MR, Hosseini SY. (2008). Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study — human (RCT; see reference 12). Journal of Urology. https://pubmed.ncbi.nlm.nih.gov/18206919/
12. Safarinejad MR, Hosseini SY (2023). Expression of Concern: Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study — editorial notice. Journal of Urology. https://pubmed.ncbi.nlm.nih.gov/36626345/
13. Rosen RC, et al. (2004). Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141 — human (clinical trial). International Journal of Impotence Research. https://pubmed.ncbi.nlm.nih.gov/14999221/
14. Diamond LE, et al. (2004). Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141 — human (clinical trial). International Journal of Impotence Research. https://pubmed.ncbi.nlm.nih.gov/14963471/
15. Diamond LE, et al. (2005). Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction — human (clinical trial). Urology. https://pubmed.ncbi.nlm.nih.gov/15833522/
16. Molinoff PB, et al. (2003). PT-141: a melanocortin agonist for the treatment of sexual dysfunction — early clinical review. Annals of the New York Academy of Sciences. https://pubmed.ncbi.nlm.nih.gov/12851303/
17. Spana C, et al. (2022). Effect of bremelanotide on body weight of obese women: data from two phase 1 randomized controlled trials — human (RCT, phase 1). Diabetes, Obesity and Metabolism. https://pubmed.ncbi.nlm.nih.gov/35170192/
18. Sauter M, et al. (2020). Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics — analytical / PK. Journal of Pharmaceutical and Biomedical Analysis. https://pubmed.ncbi.nlm.nih.gov/32353679/
19. Krupke H, et al. (2025). A biodegradable suction patch for sustainable transbuccal peptide delivery — animal (dog, delivery study). Journal of Controlled Release. https://pubmed.ncbi.nlm.nih.gov/40513668/
20. Suzuki S, et al. (2024). Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression — in vitro. Anticancer Research. https://pubmed.ncbi.nlm.nih.gov/39197897/
21. Pfaus JG, et al. (2026). Should Bremelanotide Be Considered for the Treatment of Sexual Arousal and Desire Disorders in Men? — review / opinion. Journal of Clinical Psychopharmacology. https://pubmed.ncbi.nlm.nih.gov/41960633/
22. Borland JM, et al. (2025). Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female sexual dysfunction — animal (hamster). Neuropharmacology. https://pubmed.ncbi.nlm.nih.gov/39793696/
23. Pfaus JG, et al. (2022). The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women — review (mechanism). CNS Spectrums. https://pubmed.ncbi.nlm.nih.gov/33455598/
24. Sawyer, T. K., Sanfilippo, P. J., Hruby, V. J., Engel, M. H., Heward, C. B., Burnett, J. B., & Hadley, M. E. (1980). 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proceedings of the National Academy of Sciences, 77(10), 5754-5758. https://pubmed.ncbi.nlm.nih.gov/6777774/
25. Arizona Daily Star. UA-developed synthetic hormones speed a tan. https://tucson.com/news/local/education/college/ua-developed-synthetic-hormones-speed-a-tan/article_1aa2c79c-a216-5579-aead-7d012f7e02da.html
26. US Patent 7,307,063. Melanocortin metallopeptides for treatment of sexual dysfunction. https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7307063

View all 26 references▾